Ana Fakin1, Anthony G Robson1, Kaoru Fujinami2, Anthony T Moore3, Michel Michaelides1, John Pei-Wen Chiang4, Graham E Holder1, Andrew R Webster1. 1. UCL Institute of Ophthalmology, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom. 2. UCL Institute of Ophthalmology, London, United Kingdom 3National Institute of Sensory Organs, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan 4Department of Ophthalmology, Keio University, School of Medicine, Tokyo, Japan. 3. UCL Institute of Ophthalmology, London, United Kingdom 2Moorfields Eye Hospital, London, United Kingdom 5Department of Ophthalmology, University of California, San Francisco School of Medicine, San Francisco, California, United States. 4. Casey Molecular Diagnostic laboratory, Portland, Oregon, United States.
Abstract
PURPOSE: We describe the phenotypes associated with nullizigosity and nine splicing mutations in the ABCA4 gene. METHODS: The study included 19 patients with biallelic null mutations (Group A, nullizygous), 27 with splicing mutations in the homozygous state or in trans with a null mutation (Group B), and 20 with p.G1961E in trans with a null mutation (Group C, control). Ages at onset and visual acuities were determined from medical histories. Area of decreased autofluorescence within a 30° × 30° fundus autofluorescence (FAF) image was measured with the Region Finder (N = 58). Full-field electroretinography (ERG) was performed incorporating the International Society for Clinical Electrophysiology of Vision (ISCEV) standard (N = 40). RESULTS: For groups A to C, the median ages of onset were 6, 8, and 17, respectively. Kaplan Meier survival analysis estimated that 50% of patients reached visual acuity below 20/400 at the ages of 29, 48, and 66 years, respectively. The area of reduced FAF was estimated to increase by 1.5, 1.2, and 0.03 mm2 per year, respectively, and cone-rod dystrophy was present in 10/12, 13/15, and 0/13 of cases, respectively. Splicing mutation c.5714+5G>A was associated with a significantly milder phenotype in comparison with nullizygous patients for all parameters. CONCLUSIONS: Nullizygosity for ABCA4 is associated with early onset cone-rod dysfunction with rapid progression shown by enlargement of central atrophy on FAF, decline of ERG amplitudes with age, and a high risk of reaching legal blindness by the fourth decade. Most studied splicing mutations were associated with a similarly severe phenotype. Estimated rates of progression may facilitate further genotype-phenotype correlations and inform the design of treatment trials.
PURPOSE: We describe the phenotypes associated with nullizigosity and nine splicing mutations in the ABCA4 gene. METHODS: The study included 19 patients with biallelic null mutations (Group A, nullizygous), 27 with splicing mutations in the homozygous state or in trans with a null mutation (Group B), and 20 with p.G1961E in trans with a null mutation (Group C, control). Ages at onset and visual acuities were determined from medical histories. Area of decreased autofluorescence within a 30° × 30° fundus autofluorescence (FAF) image was measured with the Region Finder (N = 58). Full-field electroretinography (ERG) was performed incorporating the International Society for Clinical Electrophysiology of Vision (ISCEV) standard (N = 40). RESULTS: For groups A to C, the median ages of onset were 6, 8, and 17, respectively. Kaplan Meier survival analysis estimated that 50% of patients reached visual acuity below 20/400 at the ages of 29, 48, and 66 years, respectively. The area of reduced FAF was estimated to increase by 1.5, 1.2, and 0.03 mm2 per year, respectively, and cone-rod dystrophy was present in 10/12, 13/15, and 0/13 of cases, respectively. Splicing mutation c.5714+5G>A was associated with a significantly milder phenotype in comparison with nullizygous patients for all parameters. CONCLUSIONS: Nullizygosity for ABCA4 is associated with early onset cone-rod dysfunction with rapid progression shown by enlargement of central atrophy on FAF, decline of ERG amplitudes with age, and a high risk of reaching legal blindness by the fourth decade. Most studied splicing mutations were associated with a similarly severe phenotype. Estimated rates of progression may facilitate further genotype-phenotype correlations and inform the design of treatment trials.
Authors: Salvador López-Rubio; Oscar F Chacon-Camacho; Rodrigo Matsui; Dalia Guadarrama-Vallejo; Mirena C Astiazarán; Juan C Zenteno Journal: Mol Vis Date: 2018-02-01 Impact factor: 2.367
Authors: Mubeen Khan; Gavin Arno; Ana Fakin; David A Parfitt; Patty P A Dhooge; Silvia Albert; Nathalie M Bax; Lonneke Duijkers; Michael Niblock; Kwan L Hau; Edward Bloch; Elena R Schiff; Davide Piccolo; Michael C Hogden; Carel B Hoyng; Andrew R Webster; Frans P M Cremers; Michael E Cheetham; Alejandro Garanto; Rob W J Collin Journal: Mol Ther Nucleic Acids Date: 2020-06-12 Impact factor: 8.886
Authors: Kaoru Fujinami; Rupert W Strauss; John Pei-Wen Chiang; Isabelle S Audo; Paul S Bernstein; David G Birch; Samantha M Bomotti; Artur V Cideciyan; Ann-Margret Ervin; Meghan J Marino; José-Alain Sahel; Saddek Mohand-Said; Janet S Sunness; Elias I Traboulsi; Sheila West; Robert Wojciechowski; Eberhart Zrenner; Michel Michaelides; Hendrik P N Scholl Journal: Br J Ophthalmol Date: 2018-06-20 Impact factor: 4.638
Authors: Frederick T Collison; Gerald A Fishman; Takayuki Nagasaki; Jana Zernant; J Jason McAnany; Jason C Park; Rando Allikmets Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799
Authors: Jana Sajovic; Andrej Meglič; Damjan Glavač; Špela Markelj; Marko Hawlina; Ana Fakin Journal: Int J Mol Sci Date: 2022-01-18 Impact factor: 5.923